key: cord-0823422-4dadwwtc
authors: Cocozza, Federico; Piovesana, Ester; Névo, Nathalie; Lahaye, Xavier; Buchrieser, Julian; Schwartz, Olivier; Manel, Nicolas; Tkach, Mercedes; Théry, Clotilde; Martin-Jaular, Lorena
title: Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus
date: 2020-07-08
journal: bioRxiv
DOI: 10.1101/2020.07.08.193672
sha: f7778dc11ac9159e57e2517314b786d7f4cef4af
doc_id: 823422
cord_uid: 4dadwwtc

SARS-CoV-2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 and subsequent priming by TMPRRS2 allowing membrane fusion. Here, we produced extracellular vesicles (EVs) exposing ACE2 and demonstrate that ACE2-EVs are efficient decoys for SARS-CoV-2 S protein-containing lentivirus. Reduction of infectivity positively correlates with the level of ACE2, is 500 to 1500 times more efficient than with soluble ACE2 and further enhanced by the inclusion of TMPRSS2.

2 SARS-CoV-2 with the surface receptor angiotensin-converting enzyme 2 (ACE2) 2 . 28

After binding to ACE2, the S protein is cleaved by TMPRSS2 and becomes fusogenic 29 thus allowing viral entry 3 . ACE2 is expressed at the surface of pneumocytes and 30

intestinal epithelial cells which are potential target cells for infection 4 . Soluble 31 recombinant ACE2 neutralizes SARS-CoV-2 by binding the S protein and has proven 32 to reduce entry of SARS-CoV-2 in Vero-E6 cells and engineered human organoids 5 . 33 ACE2 however is synthesized as a transmembrane protein, and we postulate that 34 ACE2 could be present on the surface of extracellular vesicles (EVs) which could 35 result in better efficacy as decoy to capture SARS-CoV-2. 36

EVs are lipid bilayer enclosed structures containing transmembrane proteins, 37 membrane associated proteins, cytosolic proteins and nucleic acids that are released 38 into the environment by different cell types 6 . Since EVs have the same membrane 39 orientation as the cells, they expose at their surface the extracellular domains of 40 transmembrane proteins that can bind to short-distant or long-distant targets. By 41 specifically binding to different proteins and protein-containing structures, EVs can 42 act as a decoy for virus 7 and bacterial toxins 8 , thus having a potential role as 43 therapeutic agents. 44

In order to explore the hypothesis that EVs can be used as SARS-CoV-2 decoy 45 agents we first assessed whether ACE2 can be present in EVs from two different 46 sources: 1) cell lines derived from tissues expressing ACE2; and 2) 293FT cells 47 5 soluble recombinant human ACE2 had to be used ( Figure 2H ) in accordance to 102 previous publications 5 . Altogether, these findings highlight the increased efficiency of 103

EVs containing full-length ACE2 to inhibit SARS-CoV-2-S-pseudotyped viral entry 104 when compared to the soluble protein alone. 105

Our data demonstrate that EVs containing ACE2, alone or in combination with 106 TMPRRS2, block SARS-CoV-2 Spike-dependent infection in a much more efficient 107 manner that soluble ACE2. Thus, ACE2-EVs represent a potential versatile 108 therapeutic tool to block not only SARS-CoV2 infection but also other coronavirus 109

infections that use the ACE2 receptor for host cell entry, as SARS-CoV 10 and NL63 11 . 110

The use of engineered EVs as therapeutic agents has been proposed several years 111 ago and is currently being explored in humans 12 , proving that a well-design EV 112 therapeutics against COVID-19 is feasible. 113

Note: a speculative article discussing the idea that we demonstrate experimentally 114

here was published while we were preparing this article, thus showing concomitant 115 emergence of similar scientific ideas 13 . 116

Human Caco-2 (HTB-37) and Calu-3 (HTB-55) were purchased from ATCC and 119 maintained at 37°C in a humidified atmosphere with 5% CO2. Caco2 and Calu3 cells 120 

A pneumonia outbreak associated with a new coronavirus of 221 probable bat origin

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 225